Nexalin Technology, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 72/100
What the filing says
Nexalin Technology acquired all 100 shares of PONM, Inc. (a neurostimulation software company owned by GreenLight Ventures LLC) by issuing $1.3M in Nexalin common stock in four tranches through May 2026. The deal includes: (1) a perpetual, exclusive license to PONM's cranial electrotherapy stimulation (CES) software and source code within the 'PONM Field of Use'; (2) a $10K/month collaboration agreement with GreenLight for development and support services; (3) anti-dilution protections on unissued stock; and (4) a non-compete covenant restricting GreenLight from competing in neurostimulation devices worldwide for an undisclosed period. Concurrently, Nexalin leased 904 additional sq ft (for 4,527 total) at its Houston HQ through June 2031.
Why this rating
At $14.7M market cap, a $1.3M equity acquisition of proprietary CES software IP plus ongoing consulting (worth ~$120K/year baseline) materially strengthens product/tech position. Meaningful but not transformational—still requires Nexalin development; GreenLight retains IP outside CES field.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.